HiberCell Raises $67.4M in Series B Financing; Secures $30M Debt Facility from Hercules Capital
HiberCell, a NYC-based biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, completed a Series B financing round for gross proceeds of $67.4m. Concurrent to this financing, the company closed on a $30m debt facility with Hercules Capital, Inc. (NYSE: HTGC). The Series B round included new investors Huizenga Capital Management, Monashee Investment [] The post HiberCell Raises $67.4M in Series B Financing; Secures $30M Debt Facility from Hercules Capital appeared first on FinSMEs .
HiberCell Raises $67.4M in Series B Financing; Secures $30M Debt Facility from Hercules Capital
HiberCell, a NYC-based biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, completed a Series B financing round for gross proceeds of $67.4m. Concurrent to this financing, the company closed on a $30m debt facility with Hercules Capital, Inc. (NYSE: HTGC). The Series B round included new investors Huizenga Capital Management, Monashee Investment [] The post HiberCell Raises $67.4M in Series B Financing; Secures $30M Debt Facility from Hercules Capital appeared first on FinSMEs .